CJC-1295 without DAC
79,99 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Physiological pattern of pulsatile GH secretion.
- Lower risk of desensitization compared to the DAC version.
- Improved body composition and recovery.
- Improved sleep quality, with synergistic effects when taken at night.
- Suitable for use in combination with GHRP-class peptides.
Description
CJC-1295 Without DAC
Growth Hormone / Anti-Aging
MECHANISM OF ACTION
Modified GRF(1-29): a GHRH analog without the albumin-binding fraction. Half-life of 30–60 minutes. It activates pituitary GHRH receptors to produce a physiological pulsatile release of GH. It mimics the natural pattern of hypothalamic GHRH signaling.
KEY BENEFITS
- Physiological pattern of pulsatile GH secretion.
- Lower risk of desensitization compared to the DAC version.
- Improved body composition and recovery.
- Improved sleep quality, with synergistic effects when taken at night.
- Suitable for use in combination with GHRP-class peptides.
SIDE EFFECTS AND SAFETY
Minimal at recommended doses. Mild water retention. Well tolerated.
RESEARCH AND CLINICAL NOTES
Standard GHRH analog with an established pharmacokinetic profile. Preferred in combination protocols where a pulsatile GH release pattern is desired.
TARGET PROFILE:
HGH optimization, anti-aging practices, and sports medicine; typically used in combination protocols.
Additional information
| Weight | ,26 kg |
|---|
Ingredients and Nutrition
Ingredient 1 - cucumber extract
Ingredient 2 - bilberry extract
Indications
1 capsule in the morning
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
5-Amino-1MQ
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated lipolysis and fat oxidation without thermogenic effects.
- Improved mitochondrial efficiency and ATP production.
- Supports insulin sensitivity and glucose homeostasis.
- Interest in body recomposition protocols in combination with GLP-1 agonists.
- Supports NAD+ levels relevant to cellular longevity.
New
GHK-Cu
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A significant increase in collagen synthesis and improved skin firmness.
- Accelerated healing and reduced scarring.
- Stimulation of the hair follicle and improvement in hair density.
- Systemic anti-aging effect through modulation of gene expression.
- Systemic antioxidant and anti-inflammatory action.
- Bone Regeneration and Nerve Repair in Research Models.
IGF-1 LR3
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Powerful anabolic effect: muscle hypertrophy and hyperplasia.
- Improved protein synthesis and nitrogen retention.
- Improved glucose utilization and fat oxidation.
- Accelerated injury healing and tissue regeneration.
- Extended half-life that allows for once-daily dosing.
L-carnitine
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved fat oxidation and energy production.
- Improved exercise performance and reduced fatigue.
- Cardiovascular health: reduces markers of atherosclerosis.
- Improving Insulin Sensitivity in Research on Type 2 Diabetes Mellitus.
- Male Fertility: Sperm Motility and Improved Sperm Count.
- Neuroprotective, with a preference for the acetyl-L-carnitine form for the CNS.
New
NAD+
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Optimization of cellular energy and efficiency in ATP production.
- Activation of sirtuins for the epigenetic regulation of longevity.
- Repair of DNA damage through PARP activation.
- Improved mitochondrial biogenesis.
- Cognitive clarity and support for neurological function.
- Applications in research on addiction and depression.
New
PT-141
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sexual desire in men and women.
- Improvement of erectile function via the central nervous system.
- Approved by the FDA for HSDD in premenopausal women as Vyleesi.
- Effective in patients who do not respond to PDE5 inhibitors.
- It can be used as needed, 45–90 minutes before the activity.
New
Selank
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Rapid anxiolytic effect without sedation or dependence.
- Cognitive improvement: memory consolidation and processing speed.
- Mood stabilization and resilience to stress.
- Modulation of the immune system through tuftsin activity.
- Minimal side effects compared to benzodiazepines.
- Used clinically in Russia to treat anxiety and cognitive disorders.
New
Semaglutide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Average body weight reduction of 15–17% with 2.4 mg per week.
- A 1.5–2.0% reduction in HbA1c.
- A 20% reduction in MACE in the SELECT trial among an obese, non-diabetic population.
- Remission of NASH in clinical trials.
- Reduced cravings for substances and alcohol, according to emerging data.
- Potential cognitive protection in dementia research.
